Lyell Immunopharma (LYEL) investor relations material

Strategic focus and clinical programs

• Developing next-generation cell therapies for hematologic malignancies and solid tumors, targeting large markets.

• Ronde-cel, a dual-targeting CD19/CD20 CAR T-cell therapy, is in two pivotal trials for large B-cell lymphoma, including a single-arm and a head-to-head study.

• LYL273, a novel CAR for metastatic colorectal cancer, is in phase I with promising early data and plans for rapid advancement.

Clinical trial progress and data updates

• Ronde-cel's single-arm PiNACLE study showed a 93% overall response rate and 76% complete response rate, with a median progression-free survival of 18 months.

• Safety profile is favorable, with no grade 3 or higher cytokine release syndrome and low neurotoxicity rates.

• Significant data updates for both Ronde-cel and LYL273 are expected in H2, with pivotal data and BLA submission targeted for mid-next year.

• The head-to-head PiNACLE trial in second-line LBCL is enrolling, aiming to demonstrate superiority over current CAR T therapies.

Innovation in solid tumor CAR T-cell therapy

• LYL273 targets GCC, highly and homogeneously expressed in colorectal cancer, with no need for biomarker selection.

• Early data from China showed a 40% response rate and 25-month median overall survival, outperforming current third-line therapies.

• The CAR design includes an armored mechanism to enhance expansion and activity in hostile tumor microenvironments.

• Safety data is being closely monitored, with dose escalation ongoing and no new dose-limiting toxicities at higher doses.